Loading...
Market
What percentage of mNSCLC patients will adopt Optune Lua by the end of 2025?
1
Resolution / Starting Odds
Less than 20% • 25%
20-40% • 25%
40-60% • 25%
More than 60% • 25%
Healthcare industry adoption reports
Story
FDA Approves Novocure’s Optune Lua for Metastatic NSCLC After Platinum-Based Chemotherapy
Oct 15, 2024, 06:35 PM
The US FDA has approved Novocure's Optune Lua for the treatment of metastatic non-small cell lung cancer (mNSCLC). The approval allows Optune Lua to be used concurrently with PD-1/PD-L1 inhibitors or docetaxel for adult patients who have progressed on or after a platinum-based chemotherapy regimen. This decision is based on the results of the LUNAR study, which showed a statistically significant improvement in overall survival. The study was presented at ASCO in 2023. The approval is expected to positively impact Novocure's market cap. $NVCR shares are anticipated to see an uptick following the FDA approval.
View original story
Similar markets
Europe • 25%
Asia • 25%
South America • 25%
Africa • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Optune Lua with PD-1/PD-L1 inhibitors • 25%
Sunvozertinib • 25%
Durvalumab with chemotherapy • 25%
Other • 25%
Less than 50% • 25%
50% to 74% • 25%
75% to 80% • 25%
More than 80% • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Yes • 50%
No • 50%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Ivonescimab > Keytruda • 25%
Ivonescimab = Keytruda • 25%
Ivonescimab < Keytruda • 25%
Neither has significant market share • 25%